Dr. Bechhold is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
171 Ashley Ave
Charleston, SC 29425Phone+1 843-792-1414
Summary
- Dr. Rebecca Bechhold is an oncologist in Charleston, SC. She received her medical degree from University of Louisville School of Medicine and has been in practice 39 years. She specializes in breast cancer, hematologic oncology, and hospice & palliative and is experienced in breast cancer, lung cancer, hospice and palliative care.
Education & Training
- University of Cincinnati Medical Center/College of MedicineFellowship, Hematology and Medical Oncology, 1981 - 1983
- University of Cincinnati1979 - 1981
- University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 1978 - 1981
- University of CincinnatiPGY I, 1978 - 1979
- University of Louisville School of MedicineClass of 1978
Certifications & Licensure
- SC State Medical License 2012 - 2025
- FL State Medical License 2005 - 2024
- OH State Medical License 1979 - 2017
- KY State Medical License 1997 - 2015
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Career Woman of Achievement YWCA, 2007
- Speaking of Women’s Health Honoree 2002
- Join now to see all
Publications & Presentations
PubMed
- 126 citationsEMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast CancerDenise A. Yardley, Robert Weaver, Michelle E. Melisko, Mansoor N. Saleh, Francis P. Arena
Journal of Clinical Oncology. 2015-05-10 - 43 citationsA phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response ...Denise A. Yardley, N. W. Peacock, Mythili Shastry, Howard A. Burris, Rebecca Bechhold
Breast Cancer Research and Treatment. 2015-10-27 - 3 citationsNeoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research InstituteDenise A. Yardley, John D. Zubkus, Janice F. Eakle, Rebecca Bechhold, L Finney
Clinical Breast Cancer. 2015-08-01
Authored Content
- Treading Water in the Information TsunamiJuly 2018
- Treading Water in the Information TsunamiJuly 2018
- Treading Water in the Information TsunamiJuly 2018
- Treading Water in the Information TsunamiJuly 2018
- Join now to see all
Professional Memberships
- Member
Industry Relationships
- Speakers Bureau, Novartis2006 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: